2 ABBOTINDIA share price target reports by brokerages below. See what is analyst's view on ABBOTINDIA share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
H1FY20 revenues grew 12.6% YoY to | 2053.7 crore, mainly due to strong growth in key therapies & power brands. EBITDA margins improved 169 bps YoY to 18.4% mainly due to better operational leverage and impact of Ind- As 116. Net profit grew 34.2% YoY to | 295.3 crore. Delta vis-à-vis EBITDA was mainly due to lower tax rate.
The domestic pharma industry is expected to grow in the range of 9-11% per annum. Issues such as NLEM and other regulatory aspects are mostly in the price. On the flip side, the looming threat of Jan Aushadhi and trade generics are some head winds at this juncture. However, we continue to believe in Abbott’s strong growth track in power brands and capability ofnew launches on a fairly consistent basis (100 products in the last ten years). We expect revenues, EBITDA and PAT to grow at ~12%, 14% and 17% CAGR, respectively, in FY19-21E. We arrive at a target price of Rs 10190 based on 35x FY21 EPS of Rs 291.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.